Hypera S.A. (OTCMKTS:HYPMY) Short Interest Update

Hypera S.A. (OTCMKTS:HYPMY) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 100 shares, a decrease of 99.1% from the February 28th total of 11,300 shares. Based on an average daily volume of 15,800 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company’s shares are short sold.

Hypera Trading Up 4.8 %

Hypera stock traded up $0.16 during midday trading on Thursday, reaching $3.51. The stock had a trading volume of 424 shares, compared to its average volume of 8,591. Hypera has a 52-week low of $2.64 and a 52-week high of $6.83. The company has a fifty day moving average of $3.30 and a 200 day moving average of $3.70. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of 8.78 and a beta of 0.99. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.68.

Hypera (OTCMKTS:HYPMY) last released its earnings results on Thursday, March 20th. The company reported $0.02 earnings per share for the quarter. Hypera had a return on equity of 13.18% and a net margin of 20.04%. The business had revenue of $258.56 million for the quarter.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.